Clinical Trial Update: Mangafodipir as an Adjunct to Percutaneous Coronary Intervention [Phase 2]

View source ↗

Summary

Mangafodipir was evaluated as an adjunct to percutaneous coronary intervention in a Phase 2 trial for myocardial infarction; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• Mangafodipir (Mangafodipir trisodium)

Snippet

Sponsor: Egetis Therapeutics | Conditions: Myocardial Infarction | Phase 2 | Status: COMPLETED